The influence of the bisphosphonate zoledronic acid (ZA) on prostate cancer (PC) growth, adhesion and invasive behavior was investigated. METHODS: PC-3, DU-145 and LNCaP cells were treated with ZA, and tumor-cell growth was then investigated by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Furthermore, tumor-cell adhesion to vascular endothelium or to immobilized extracellular matrix proteins, as well as migratory properties of the cells, was evaluated. Integrin b subtypes, integrin-dependent signaling, as well as cell-cycle regulating proteins, were analyzed by western blots. RESULTS: ZA dose-dependently reduced tumor-cell growth but did not impair tumor --endothelium and tumor --matrix interaction. However, ZA significantly inhibited tumor migration and invasive activity. Cyclin E was reduced by ZA in LNCaP and DU-145, and p21 was elevated in LNCaP cells. p27 was upregulated in all tumor cell lines, compared with the controls. ZA elevated b1-integrin in PC-3 and diminished b4-integrin in PC-3 and DU-145 cells. CONCLUSION: ZA inhibits PC growth and motility but does not influence the mechanical contact between tumor cells and the vascular wall.
INTRODUCTION
Close to 90% of men with metastatic castration-resistant prostate cancer (PC) have radiographically detectable bone metastases that cause pain and greatly increase fracture risk and other structural complications. 1, 2 In 2002, zoledronic acid (ZA; Zometa) was introduced as the first FDA-approved osteoclast-targeting bisphosphonate. It is used to treat bone metastases in patients with PC and other solid tumors because of its ability to reduce skeletal complications. 3 ZA, as a nitrogen-containing bisphosphonate, inhibits the mevalonate pathway and protein prenylation, resulting in inhibition of osteoclast-mediated bone resorption, as well as osteoclast apoptosis. 4 This mechanism ultimately prevents hypercalcemic episodes and increases the quality of life in affected patients.
Clinical studies point towards improved overall survival in patients treated with ZA, compared with placebo. 5 This has been underlain by an in vivo model, presenting evidence that ZA may prolong life span of the patient. 6 According to this report, preclinical experiments with several cancer cell lines demonstrated direct anticancer activities of ZA through inhibition of tumor-cell proliferation and viability. 7 --10 The relevance of ZA in PC is still not clear. ZA treatment has been shown to stop growth of prostate tumor cells in vitro but not to evoke cell death. 11 Other investigators have reported decreased cell viability with this compound. 12 In another experimental setting, ZA markedly inhibited PC cell growth through a variable combination of cytostatic and apoptotic effects. 13 In vitro data provided by Clyburn et al. have reported only minor effects of ZA on apoptosis.
14 Information about the effect of ZA on the motile behavior of PC cells, which is a necessary prerequisite to metastatic spread, is particularly sparse. Therefore, the impact of ZA on growth, adhesive activity and migration of several PC cell lines and respective molecular mechanisms was investigated.
MATERIALS AND METHODS

Cell cultures
Human PC cell lines PC-3, DU-145 and LNCaP were obtained from DSMZ (Braunschweig, Germany). Tumor cells were grown and subcultured in RPMI 1640 (Gibco/Invitrogen, Karlsruhe, Germany), 10% fetal calf serum, 20 mM HEPES-buffer, 2% glutamine and 1% penicillin/streptomycin.
Human endothelial cells (HUVECs) were isolated from human umbilical veins and harvested by enzymatic treatment with chymotrypsin. HUVECs were grown in Medium 199 (Biozol, Munich, Germany), 10% fetal calf serum, 10% pooled human serum, 20 mg ml À1 endothelial cell growth factor (Boehringer, Mannheim, Germany), 0.1% heparin, 100 ng ml À1 gentamycin and 20 mM HEPES-buffer. ZA ZA (provided by Novartis Pharma AG, Basel, Switzerland) was dissolved in RPMI 1640 as 10 mM stock solution and stored in aliquots at À20 1C. Prior to the experiments, ZA was diluted in cell-culture medium to reach the final concentration indicated in the Results section.
Measurement of tumor-cell growth
Cell proliferation was assessed using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide dye reduction assay (Roche Diagnostics, Penzberg, Germany). Treated versus nontreated PC-3, DU-145 or LNCaP cells (0.5 Â 10 4 cells per well) were seeded onto 96-well tissue culture plates. After 24, 48 and 72 h, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (0.5 mg ml À1 ) was added for an additional 4 h. Thereafter, cells were lysed in a buffer containing 10% SDS in 0.01 M HCl. The plates were allowed to stand overnight at 37 1C, 5% CO 2 . Absorbance at 570 nm was determined for each well using a microplate enzyme-linked immunosorbent assay reader. Each experiment was done in triplicate. After subtracting background absorbance, results were expressed as mean cell number.
Apoptosis and necrosis
To exclude toxic effects of the compounds, cell viability was determined by trypan blue (Gibco/Invitrogen). For apoptosis detection, the expression of Annexin V/propidium iodide (PI) was evaluated using the Annexin V-FITC Apoptosis Detection kit (BD Pharmingen, Heidelberg, Germany). Tumor cells were washed twice with phosphate-buffered saline (PBS) and then incubated with 5 ml of Annexin V-FITC and 5 ml of PI in the dark for 15 min at room temperature. Annexin V binds with high affinity to the membrane phospholipid phosphatidylserine, which is translocated from the inner to the outer leaflet of the plasma membrane during early apoptosis. Because the membranes are intact in early apoptosis, cells are impermeable for the vital dye PI, that is, cells are FITC Annexin V-positive and PI-negative. Late apoptosis is characterized by a loss of the membrane integrity, thus cells are both FITC Annexin V-and PI-positive.
Cells were analyzed on a FACScalibur (BD Biosciences, Heidelberg, Germany). Early apoptotic cells were visualized in the lower right quadrant and late apoptotic cells in the upper right quadrant. The percentage of apoptotic cells (early and late) in each quadrant was calculated using CellQuest software (BD Biosciences).
Tumor-cell adhesion
To analyze tumor-cell adhesion, HUVECs were transferred to six-well multiplates (Falcon Primaria; BD Biosciences). When confluency was reached, PC-3, DU-145 or LNCaP cells (pretreated with ZA for 1 or 24 h) were detached from the culture flasks by accutase treatment (PAA Laboratories, Cö lbe, Germany) and 0.5 Â 10 6 cells were then added to the HUVEC monolayer for 30, 60 or 120 min. Subsequently, nonadherent tumor cells were washed off using warmed (37 1C) Medium 199. The remaining cells were fixed with 1% glutaraldehyde. Adherent tumor cells were counted in five different fields of a defined size (5 Â 0.25 mm 2 ) using a phase-contrast microscope and the mean cellular adhesion rate was calculated.
Attachment to extracellular matrix components
Six-well plates were coated with collagen G (extracted from calfskin, consisting of 90% collagen type I and 10% collagen type III; Seromed; diluted to 400 mg ml À1 in PBS), laminin (derived from the Engelbreth --Holm --Swarm mouse tumor; BD Biosciences; diluted to 50 mg ml À1 in PBS) or fibronectin (derived from human plasma; BD Biosciences; diluted to 50 mg ml À1 in PBS) overnight. Unspecific cell binding was evaluated by culture plates treated with Poly-D-Lysin (Nunc, Wiesbaden, Germany). Plastic dishes were served as the background control.
Plates were washed with 1% bovine serum albumin in PBS to block nonspecific cell adhesion. Thereafter, 0.5 Â 10 6 tumor cells (pretreated with ZA for 1 or 24 h) were added to each well for 60 min. Subsequently, nonadherent tumor cells were washed off, the remaining adherent cells were fixed with 1% glutaraldehyde and counted microscopically. The mean cellular adhesion rate, defined by adherent cells coated well --adherent cells background , was calculated from five different observation fields.
Cell migration and invasion
Serum-induced cell migration and invasion was examined using six-well Transwell chambers (Greiner, Frickenhausen, Germany) with 8-mm pores. A total of 0.5 Â 10 6 tumor cells per ml were incubated with ZA for 1 or 24 h, or remained untreated. To evaluate cell migration, cells were then placed in the upper chamber for 20 h in serum-free medium. The lower chamber contained 10% serum. After incubation, the upper surface of the Transwell membrane was wiped gently with a cotton swab to remove nonmigrating cells. Cells that migrated to the lower surface of the membrane were stained using hematoxylin and counted. Cells that migrated into the lower chamber were counted separately by microscopy. To evaluate cell invasion, Transwell chambers were coated with collagen (400 mg ml À1 ). Treated versus nontreated tumor cells were then added and the number of cells that migrated to the lower membrane surface or into the lower compartment was counted. Results are shown as % inhibition, compared with the 100% untreated control.
Western blot analysis
To explore cell-cycle regulating proteins, as well as integrin level and signaling, tumor-cell lysates were applied to a 7% polyacrylamide gel and electrophoresed for 90 min at 100 V. The protein was then transferred to nitrocellulose membranes. After blocking with nonfat dry milk for 1 h, the membranes were incubated overnight with monoclonal antibodies directed against cell-cycle proteins: cyclin B (clone 18), cyclin E (clone HE12), p21 (clone 2G12), p27 (clone 57; all: BD Biosciences). Integrins were analyzed using monoclonal antibodies directed against the following integrin subtypes: anti-b1 (clone MAR4), anti-b4 (clone 439 --9B; all: BD Biosciences). Integrin-related signaling was explored by anti-integrinlinked kinase (clone 3), anti-focal adhesion kinase (clone 77) and antiphospho-specific focal adhesion kinase (pFAK, pY397 and clone 18) antibodies (all: BD Biosciences). HRP-conjugated goat-anti-mouse IgG (Upstate Biotechnology, Lake Placid, NY, USA) served as the secondary antibody. The membranes were briefly incubated with ECL detection reagent (ECL Amersham/GE Healthcare, Mü nchen, Germany) to visualize the proteins and exposed to an X-ray film (Hyperfilm EC Amersham/GE Healthcare). b-actin (Sigma, Taufkirchen, Germany) served as the internal control.
Statistics
All experiments were performed three to six times. Statistical significance was investigated by the Wilcoxon Mann --Whitney U-test. Differences were considered statistically significant at a P-value o0.05.
RESULTS
ZA diminishes tumor-cell growth ZA significantly and dose-dependently inhibited the growth of PC-3 (X5 mM), LNCaP (X5 mM) or DU-145 (X10 mM) cells (Figure 1a) , compared with the untreated controls. The 72-h values were even below the 24-h values with respect to the application of 100 mM ZA in PC-3 and DU-145 cells. A significant increase of early apoptosis was seen in PC-3 and DU-145 cells (PC-34DU-145) when exposed to ZA for 72 h (Figure 1b) , whereas no effects were induced after a 4-h exposure (data not shown). Moderate upregulation of cells undergoing late apoptosis was observed in LNCaP cultures after a 72-h drug exposure to 100 mM ZA. Viability of PC-3 and DU-145 cells was slightly diminished when treated with 50 mM ZA but distinctly reduced in all cell lines in the presence of 100 mM ZA (PC-34DU-1454LNCaP).
Tumor-cell adhesion ZA did not downregulate PC-3 cell attachment to immobilzed collagen, laminin or fibronectin. The binding of PC-3 cells to fibronectin and laminin was even slightly enhanced by 25 mM ZA, compared with untreated cells (Figure 2, 24 h pretreatment) . Attachment of DU-145 and LNCaP cells to collagen and fibronectin was not impaired by 10, 25 or 50 mM ZA, but 100 mM did impair attachment. A total of 100 mM ZA also diminished DU-145 adhesion to laminin. Because untreated LNCaP cells only marginally bound to laminin, drug-induced effects on LNCaP laminin interaction were not analyzed.
The tumor-cell HUVEC co-culture assay revealed a significant loss of adherent cells, particularly when tumor cells were pretreated with 50 mM (PC-3, LNCaP) or 100 mM (all cell lines) ZA for 24 h (Figure 3 ). Concentrations o50 mM did not modify the adhesion behavior of tumor cells.
ZA alters tumor-cell motility Figure 4 demonstrates the influence of ZA on tumor-cell migration (Figure 4a ) and invasion (Figure 4b) . The experiments were carried out with 25 mM, because higher doses have partially triggered apoptotic or toxic activities (Figure 1b) . In doing so, migration of PC-3 and DU-145 was distinctly lowered by ZA, whether the cells were pretreated with this compound for 1 h or 24 h (Figure 4a ). In contrast, LNCaP cells responded to 25 mM ZA following a 1-h but not a 24-h preincubation.
Tumor-cell invasion through a collagen matrix was also investigated. Overall, both a 1-h and a 24-h drug pretreatment led to a reduction of cells crossing the Transwell membrane. With respect to LNCaP cells, the 24-h effect was restricted to those cells which moved into the lower chamber (Figure 4b ).
ZA modifies intracellular signaling
Signaling analysis was investigated with 25 mM ZA. It was administered for 1 h and 24 h to evaluate proteins related to tumor adhesion and migration or for 24 h and 72 h to evaluate proteins related to tumor growth. The expression of the adhesionrelevant molecules, integrin-linked kinase and focal adhesion kinase (both total and activated), were not altered by ZA in all cell lines. However, b1-integrin was elevated, b4-integrin reduced in PC-3 cells, compared with the controls (Figure 5a ). b4-integrin was also found to be diminished in DU-145 cells following ZA exposure. LNCaP did not express this subtype.
The growth controlling protein cyclin B was similarly expressed in treated versus nontreated tumor cells, whereas cyclin E was diminished in LNCaP and DU-145 cells under ZA (Figure 5b ). Drugtreated LNCaP cells were also characterized by elevated p21. Enhanced expression of p27 was detected in all cell lines after 24 h (PC-3) and 72 h (LNCaP, DU-145, PC-3).
DISCUSSION
ZA diminished the growth of a panel of PC cell lines. The mechanistic background is not clear. Upregulation of proapoptotic genes accompanied by the downregulation of antiapoptotic genes might be one means of how ZA reduces the tumor-cell number. 15 apoptosis in PC-3 and DU-145 and late apoptosis in LNCaP cells only at 100 mM ZA. Based on this, apoptosis induction does not seem to be the main mechanism responsible for ZA-evoked tumor-growth inhibition. In fact, Clyburn et al.
14 have observed an apoptosis rate o2% when PC cell lines were exposed to 5 mM ZA, although this dosage was sufficient to significantly stop tumor-cell proliferation. In a further study, the maximum dose of 100 mM ZA triggered apoptosis only marginally in LNCaP cells, as assessed by flow cytometry. 17 The present data point to the cell-cycle regulating protein cyclin E as a relevant target of ZA. It has been shown that cyclin E promotes PC cell proliferation through activation of the PI3K/Akt 1h-membrane 1h-chamber 24h-membrane 24h-chamber 1h-membrane 1h-chamber 24h-membrane 24h-chamber 1h-membrane 1h-chamber 24h-membrane 24h-chamber Figure 4 . Zoledronic acid acts on (a) tumor-cell migration and (b) invasion as assessed in a Transwell-chamber assay. To evaluate the migratory potential, drug treated (25 mM, 1 or 24 h preincubation) versus nontreated (control) PC-3, DU-145 or LNCaP cells were seeded in the upper chamber and 10% serum as the chemoattractant was placed in the lower well. Invasion was analyzed by adding the prostate cancer cells to the upper chamber that was coated with collagen. Cells that migrated to the lower surface of the membrane were stained using hematoxylin and counted (membrane). Cells that moved into the lower compartment were counted separately (chamber). Controls were set to 100%. * indicates significant difference to controls.
pathway. 18, 19 Consequently, loss of cyclin E evoked by ZA might be important (at least partially) for diminishing the growth capacity of the tumor cells. No data are available dealing with the influence of ZA on cyclin E in PC. However, the anti-tumor potential of ZA was characterized recently by the decreased activation of the Akt-dependent pathways in a PC in vitro model, which supports our hypothesis. 20 Because downmodulation of cyclin E was seen in DU-145 and LNCaP, but not in PC-3 cells, this mechanism cannot be generalized. Rather, cyclin E might be sensitive to ZA treatment in particular tumor subpopulations. The same seems to be true for p21, expression of which was altered in LNCaP but not in PC-3 and DU-145 cells. Interestingly, the tumor-suppressor protein p27 was augmented in all cell lines investigated. This is important, because p27 loss has been attributed to acceleration of proliferation and transformational activity of PC cells. 21, 22 p27 is meanwhile considered to be a powerful prognostic marker for PC recurrence and outcome. 23, 24 Therefore, lowering the p27 expression level in PC by ZA might be a characteristic attribute of this agent, leading to impaired cell-cycle progression. Because p27 expression is also modified via the mTOR signaling pathway, 25 the combination of an mTOR inhibitor with ZA might be an elegant concept to strongly diminish p27-driven tumor progression. In fact, in vitro and in vivo studies have demonstrated that ZA plus Everolimus (RAD001) augment the growth-blocking effect seen with either drug alone. 26, 27 Clinical trials have indicated a reduced incidence of skeletalrelated events in men with hormone-refractory metastatic PC treated with ZA. 5 Hence, it has been argued that ZA may directly influence metastatic tumor spread. Our data only partially confirm this speculation. Tumor-cell adhesion to the extracellular matrix, as well as to vascular endothelium, was significantly diminished at concentrations X50 mM. However, this may not be a direct effect, because viability was reduced when the tumor-cell cultures were exposed to 50 or 100 mM ZA. Presumably, ZA does not block the mechanistic cross-talk between circulating cancer cells and the vascular wall. An interesting aspect was seen with the 25-mM dosage, which slightly but significantly elevated the number of PC-3 cells attached to a fibronectin or laminin matrix. The data can be interpreted in two ways. Either an increased attachment rate may allow more cells to transmigrate or an increased attachment is coupled to reduced motile behavior, preventing transendothelial penetration. Novel in vitro experiments, together with a forcebased computational model, have demonstrated that PC cell adhesion may be inversely correlated to the migration speed. 28 Keeping this in mind, 25 mM ZA significantly impeded PC-3 migration and invasion in our experiments, favoring this scenario. Nevertheless, movement of DU-145 and LNCaP cells (adhesion of which was not modified by ZA) was also reduced, which points to an adhesion-independent effect of ZA. The observation that lowdosed ZA prevents the migration of all prostate tumor cell lines is important because active crawling is a prerequisite to metastasis. Consequently, intervention in this process may render the tumor cells unable to disseminate into the target organ. Few reports deal with this issue. Boissier et al. 29 reported that ZA inhibits the invasion of the metastatic PC cell line PmPC3 through matrigel but not chemotaxis towards a serum gradient. Another study provided evidence that 50 mM ZA diminishes PC-3 invasion in a matrigel Boyden chamber assay. However, lower concentrations were not applied in these experiments. 20 Treatment of PC-3 cells with ZA above 5 mM resulted in a significant reduction in invasion across bone-marrow endothelium. 30 Collectively, investigations have shown that ZA exerts anti-invasive properties on PC. The mechanism is still unclear. Western blot analysis demonstrated elevated b1-integrin expression level in PC-3 cells and a diminished b4-expression in PC-3 and DU-145 cells treated with ZA. Loss of b1-integrin is considered to promote PC cell invasion and metastasis by reducing cancer-cell adhesion. Reexpression of b1 has been shown to convert a neoplastic phenotype to a nonproliferative and highly adherent normal phenotype. 31 This is consistent with microarray data of PC patients presenting evidence that b1-integrin expression negatively correlates with metastasis. 32 Reduction of b4 integrin has been correlated with a low invasive phenotype of PC cells, 33 and upregulation of integrin b4 has resulted in a concomitant increase in PC transmigration. 34 Elevation of b1 along with downregulation of b4 might be one mechanism explaining how ZA acts on PC-3 and DU-145 motility. Another mode of action must, however, be assumed for the LNCaP cell line. Indeed, LNCaP responded differently to ZA in the migration assay, compared with PC-3 and DU-145. Only the short ZA preincubation time of 1 h diminished migration, whereas long-term pretreatment was ineffective. It has recently been postulated that the cell-cycle inhibitor p21 may exert anti-metastatic activities in PC. 35 Because p21 was upregulated in LNCaP cells, but not in PC-3 and DU-145 cells, following ZA exposure, ZA might control LNCaP motility and invasion via this molecule. This novel finding has not been dealt with by others. Therefore, our interpretation is still speculative. Further, experiments are necessary to clarify the role of p21 in PC metastasis. 
